[link removed]
[link removed] [link removed]
View this email in your browser ([link removed])
BREAKING NEWS ALERT
Johnson & Johnson’s closely watched experimental COVID-19 vaccine prevented 66 percent of moderate and severe global cases in a large late-stage study, the company said Friday.

The vaccine, which uses technology pioneered by the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston, prevented 72 percent of US cases in the clinical trial, which involved about 45,000 volunteers across the world.

Read the full story on BostonGlobe.com. ([link removed])
Subscribe to BostonGlobe.com ([link removed])
------------------------------------------------------------
We have lots of e-mail newsletters on a variety of topics, including news, politics, business, sports, lifestyle, and more. They're free, and it's easy to subscribe. Here's a complete list. ([link removed])
------------------------------------------------------------
[link removed]
[link removed] [link removed]

============================================================
** Like us ([link removed])
** Follow us ([link removed])
You received this message because you signed up for Breaking News Alerts.

Copyright © 2021 The Boston Globe, All rights reserved.

Our mailing address is:
The Boston Globe
1 Exchange Place Suite 201
Boston, MA 02109-2132
USA

** unsubscribe from this list ([link removed])

** Manage Your Account ([link removed])
| ** Terms of Service ([link removed])
| ** Privacy Policy ([link removed])
| ** Help Center ([link removed])
| ** Advertise (mailto:[email protected]?subject=Advertising+in+BostonGlobe.com)